Cargando…

Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series

Leptomeningeal metastasis (LM) is a lethal complication of advanced non-small cell lung cancer (NSCLC) with rapid deterioration and poor prognosis. It has no standard treatment for epidermal growth factor receptor mutation (EGFRm) NSCLC, and improving the clinical outcomes for patients with LM has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuhai, Zhang, Meilin, Cheng, Wanwan, Fang, Shencun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685536/ https://www.ncbi.nlm.nih.gov/pubmed/36439478 http://dx.doi.org/10.3389/fonc.2022.1040450

Ejemplares similares

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

Almonertinib plus chemotherapy versus almonertinib alone in second-line treatment of advanced non-small cell lung cancer with mutated epidermal growth factor receptor: a retrospective study
por: Fang, Xiaoxu, et al.
Publicado: (2023)

Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
por: Feng, Shao, et al.
Publicado: (2022)

Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
por: Pan, Hai, et al.
Publicado: (2023)

In vivo evaluation of the pharmacokinetic interactions between almonertinib and rivaroxaban, almonertinib and apixaban
por: Wang, Zhi, et al.
Publicado: (2023)

Survival Outcomes of Patients With Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
por: Li, Ning, et al.
Publicado: (2022)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
por: Zhang, Hui, et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Editorial: Brain and leptomeningeal metastases in lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2023)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

Almonertinib-induced interstitial lung disease: A case report
por: Jiang, Ting, et al.
Publicado: (2021)

Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer
por: Zhao, Wei, et al.
Publicado: (2022)

Treatment Response To Osimertinib In EGFR-Mutated Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Series
por: Li, Huiying, et al.
Publicado: (2019)

An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases
por: Tsuchiya, Kazuo, et al.
Publicado: (2018)

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment
por: Dong, Changqing, et al.
Publicado: (2022)

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases
por: Yang, Gang, et al.
Publicado: (2022)

Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer
por: Fang, Shencun, et al.
Publicado: (2020)

CyberKnife Radiosurgery for Spinal Leptomeningeal Metastases Secondary to Esthesioneuroblastoma: A Clinical Case Report
por: Zamarud, Aroosa, et al.
Publicado: (2023)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Combination of Atezolizumab, Bevacizumab, and Chemotherapy (IMpower 150) in a Patient With NSCLC Having Leptomeningeal Metastases
por: Remon, Jordi, et al.
Publicado: (2020)

Comparison of the diagnostic value of liquid biopsy in leptomeningeal metastases: A systematic review and meta-analysis
por: Wang, Hanbin, et al.
Publicado: (2022)

Case report: The treatment for olfactory neuroblastoma combined with leptomeningeal carcinomatosis via an ommaya reservoir
por: Peng, Yichen, et al.
Publicado: (2023)

A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer
por: Pan, Zhenyu, et al.
Publicado: (2019)

Predictors of Lung Adenocarcinoma With Leptomeningeal Metastases: A 2022 Targeted-Therapy-Assisted molGPA Model
por: Zhang, Milan, et al.
Publicado: (2022)

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
por: Yang, James C.H., et al.
Publicado: (2020)

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status
por: Xu, Haiyan, et al.
Publicado: (2021)

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
por: Le Rhun, Emilie, et al.
Publicado: (2013)

Development and Validation of a UHPLC–MS/MS Method for Quantitation of Almonertinib in Rat Plasma: Application to an in vivo Interaction Study Between Paxlovid and Almonertinib
por: Tang, Peng-fei, et al.
Publicado: (2022)

Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
por: Xu, Hongyu, et al.
Publicado: (2020)

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors
por: Burger, Michael C., et al.
Publicado: (2016)

Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
por: Shen, Gang, et al.
Publicado: (2021)

FLAIR hyperintensity along the brainstem surface in leptomeningeal metastases: a case series and literature review
por: Mitsuya, Koichi, et al.
Publicado: (2020)

Leptomeningeal Carcinomatosis in Recurrent Non-Small Cell Lung Cancer: A Case Report and Review of Current Treatment Modalities
por: Abbasi, Saqib, et al.
Publicado: (2017)

A case report of endometrial adenocarcinoma with leptomeningeal metastases
por: Fazilat‐Panah, Danial, et al.
Publicado: (2021)

Almonertinib as a neoadjuvant therapy for patients with a superior pulmonary sulcus tumor with activated EGFR mutation: A case report
por: Kang, Kai, et al.
Publicado: (2023)

Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report
por: Webb, Mason J, et al.
Publicado: (2023)

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
por: Kelly, William J., et al.
Publicado: (2018)

Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
por: ZHU, Lucheng, et al.
Publicado: (2021)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n5ni7alsstgee2vt6t6aqmvnrh